Risks Downplayed As Boston Scientific Nears Guidant Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific claims it can handle the debt it will incur from its approximately $28 bil. acquisition of Guidant and that it has the history to prove it
You may also be interested in...
Boston Scientific Bemoans ICD Market Slide, Cements Cardiovascular Focus
Boston Scientific may have to adjust revenue projections for its newly acquired Guidant unit due to slowdowns in the cardiac rhythm management market
Boston Scientific Bemoans ICD Market Slide, Cements Cardiovascular Focus
Boston Scientific may have to adjust revenue projections for its newly acquired Guidant unit due to slowdowns in the cardiac rhythm management market
Warning Letter Should Not Hinder Taxus Liberté Approval – Boston Scientific
Boston Scientific estimates it will be ready by June for FDA to re-inspect its facilities to confirm that the quality-control problems cited in a sweeping Jan. 25 warning letter have been fixed